 Home > Active Ingredient News > Study of Nervous System > JNNP: Anti-CD20 monoclonal antibody therapy reduces the humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or optic neuromyelitis

JNNP: Anti-CD20 monoclonal antibody therapy reduces the humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or optic neuromyelitis

 Last Update: 2021-08-13
 Source: Internet
 Author: User

Tags

serum buy

serum aldolase

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Since the outbreak of COVID-19, anti-CD20 monoclonal antibody therapy has been used to reduce the humoral immune response of patients with multiple sclerosis or neuromyelitis optica to SARS-CoV-2

Therefore, multiple sclerosis patients among COVID-19 infected persons are at higher risk of severe and/or long-term symptoms

As with any viral infection, the cellular and humoral immune response is expected to prevent re-infection

This article conducted a prospective study to evaluate the seroprevalence and anti-S IgG, anti-S IgA, and anti-N IgG in a cohort of MS or neuromyelitis optica (NMO-SD) patients receiving or not receiving immunomodulatory or immunosuppressive therapy Level

This article conducted a single-center prospective study to collect serum samples from patients with MS or NMO-SD in order to determine the characteristics of COVID-19 in MS or NMO-SD

Patient inclusion criteria are: age ≥18 years, at least one of the following criteria for COVID-19 diagnosis: (1) based on positive nasopharyngeal swabs (2) typical chest CT abnormalities (ground glass shadows), (3) typical symptoms (Weakness, difficulty breathing, cough, fever)

SARS-CoV-2 serology in each DMT group in patients with multiple sclerosis or optic neuromyelitis spectrum disorder

The blood sample was centrifuged at 4°C, and then 2 mL of serum was divided into 4 equal aliquots of 500 uL

Anti-IgG titers in the DMT group of patients with multiple sclerosis or optic neuromyelitis spectrum disorder

A total of 119 patients (115 MS, 4NMO, average age: 43.

Regarding total Ig levels, patients taking interferon and glatiramycin acetate had higher IgG levels than other groups (p=0.

96/119 (80.

In summary, in MS or NMO-SD patients receiving anti-CD20 therapy, the SARS-CoV-2 antibody response is reduced

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Quality Pregabalin 99% powder 148553-50-8 -Shaanxi Dideu Medichem Co.Ltd

CAS No.: 148553-50-8

Chemical Grade

$1/KG FOB

Pregabalin (CNS)

CAS No.: 148553-50-8

Pharmacy Grade

$1/KG FOB

Primidone CAS125-33-7

CAS No.: 125-33-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.